Comparative Pharmacology
Head-to-head clinical analysis: ALLERFED versus DRIXORAL PLUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLERFED versus DRIXORAL PLUS.
ALLERFED vs DRIXORAL PLUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALLERFED is a combination of an antihistamine (fexofenadine) and a decongestant (pseudoephedrine). Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine effects, reducing allergy symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor activation, causing vasoconstriction of nasal mucosa.
DRIXORAL PLUS contains dexbrompheniramine, an antihistamine that competes with histamine for H1-receptor sites, suppressing histamine-induced symptoms; and pseudoephedrine, a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
1 tablet (pseudoephedrine 60 mg / triprolidine 2.5 mg) orally every 4-6 hours; not to exceed 4 doses per 24 hours.
1 tablet orally every 12 hours, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life 20-24 hours; clinically significant for once-daily dosing in seasonal allergic rhinitis.
Pseudoephedrine: ~9-16 hours (pH-dependent, longer in alkaline urine). Dexbrompheniramine: ~20-25 hours. Clinical context: multiple dosing accumulates.
Primarily renal (approximately 60-70% as unchanged drug and metabolites); minor biliary (10-15%); fecal (5-10%).
Renal: 50-70% unchanged for pseudoephedrine; hepatic metabolism for dexbrompheniramine with renal excretion of metabolites.
Category C
Category C
Decongestant
Antihistamine/Decongestant